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In a population with moderate COPD, at heightened cardiovascular risk and containing a
substantial proportion of individuals with BMI ⩾40 kg/m2, BMI and mortality demonstrate a
U-shaped (rather than J-shaped) relationship https://bit.ly/3hDztI6
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Abstract
Populations with COPD demonstrate higher survival in overweight and obese compared with normal
weight; the “obesity paradox”. Relationships in less-severe COPD are unclear, as is the impact of
cardiovascular risk, and few studies include individuals at extremes of obesity.
We examined the relationship between body mass index (BMI; defined as underweight: <20 kg·m−2,
normal: 20–25 kg·m−2, overweight: 25–<30 kg·m−2, obese class I: 30–<35 kg·m−2, class II: 35–
<40 kg·m−2 and class III: ⩾40 kg·m−2), morbidity, and mortality in the SUMMIT trial population (n=16
485), characterised by moderate COPD and heightened cardiovascular risk with a substantial proportion
with class III obesity. The association between BMI category and time to event was modelled via
proportional hazards (reference normal weight) adjusted for demographics and cardiorespiratory disease.
Consistent with the paradox, underweight individuals demonstrated higher mortality (hazard ratio (HR)
1.31 (95% CI 1.04–1.64)), with lower mortality among overweight (HR 0.62 (95% CI 0.52–0.73)) and
obese class I (HR 0.75 (95% CI 0.62–0.90)). However, mortality increased in obese class III (HR 1.36
(95% CI 1.00–1.86)). Death was primarily attributable to cardiovascular causes.
Within a large, multinational cohort with moderate COPD and increased cardiovascular risk, the
phenomenon of reduced mortality with obesity did not persist at BMI >40 kg·m−2, suggesting that obesity
may not remain protective at the extremes in this population.
Introduction
Previous studies in COPD populations demonstrate improved survival in overweight and obese compared
with normal weight individuals, and increased mortality in the underweight [1, 2]. This reverse “J-shaped”
curve is referred to as the “obesity paradox”, and has been described in several other chronic disease states
[3–5]. In the general population, however, the relationship between body mass index (BMI) and survival is
“U-shaped” with an increase in mortality noted both with underweight compared with normal weight
individuals, and again with increasing BMI/obesity [6, 7]. It remains unclear why the “U-shaped” curve
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has not been reflected in populations with COPD. Several hypotheses are proposed to explain this
discrepancy, including sparse data on patients with COPD at the extremes of obesity.
Furthermore, the paradox has been most apparent in patients with severe disease (defined by lower forced
expiratory volume in 1 s (FEV1)) [2, 8]. Whether the paradox applies to patients with milder disease is
uncertain. Relationships between BMI and cause-specific mortality in COPD are largely undefined, and
associations with morbidity in the same population is often unexplored. Cardiovascular disease is a
common comorbidity in COPD [9, 10] and a major cause of death [11, 12], but cardiovascular risk is often
not described in studies of the obesity paradox.
The SUMMIT (Study to Understand Mortality and Morbidity In COPD) trial was conducted in a large,
international population with moderate COPD at heightened cardiovascular risk [13]. Over 16000 patients
were randomised to inhaler therapies including fluticasone furoate and/or vilanterol, with similar mortality
rates regardless of treatment assignment. Standardised adjudication of all deaths and cardiovascular events
was performed. COPD exacerbations were captured as protocol-defined events. A substantial number of
individuals (over 500) had class III obesity (BMI ⩾40 kg·m−2), presenting an ideal opportunity to
investigate the obesity paradox over a wide range of BMI. Because cause of death and cardiopulmonary
morbidity events were also captured as outcomes, we additionally investigated the association between
BMI category and cause-specific mortality rates, COPD exacerbation rates, and cardiovascular event rates.
Methods
Study subjects
All participants in the SUMMIT trial [13] in the intent-to-treat population were included in the present
analysis, with basic eligibility criteria including: age 40–80 years, moderate COPD (defined as FEV1/
forced vital capacity (FVC) ⩽0.70, and FEV1 of 50–70% of predicted values [14, 15], at least
10 pack-years smoking history, and modified Medical Research Council (mMRC) score of 2 or greater),
and history of or risk factors for cardiovascular disease. A complete listing of eligibility criteria is
published elsewhere [16] All participants in the current analysis provided written, informed consent for
trial participation. The SUMMIT trial was approved by local ethics committees and conducted in
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Study design
We present a post hoc analysis of trial results. As detailed in previous trial descriptions [13, 16], 16485
patients from 43 countries were included in the intention-to-treat efficacy population, and randomised
1:1:1:1 to once-daily inhaled placebo, fluticasone furoate (100 μg), vilanterol (25 μg), or the combination
of fluticasone and vilanterol. Participants were seen every 3 months after randomisation to document vital
status and adverse events. The trial opened enrolment on January 24, 2011 and completed data collection
July 15, 2015.
BMI was obtained at enrolment. Overweight (BMI 25–<30 kg·m−2), obese class I (BMI 30–<35 kg·m−2),
class II (BMI 35–<40 kg·m−2) and class III (BMI ⩾40 kg·m−2) were defined by World Health
Organization (WHO) criteria. Normal weight was considered BMI 20–<25 kg·m−2, with underweight as
<20 kg·m−2 and separately as <18.5 kg·m−2 (sensitivity analysis, WHO criteria [17]).
The primary outcome in this analysis and in the original trial was all-cause mortality, defined as time to
on- and post-treatment death. A secondary outcome of cause-specific mortality was adjudicated by a
clinical end-point committee using a combination of study data, death certificates, autopsy findings, and
health records. Respiratory morbidity outcomes included on-treatment moderate COPD exacerbations,
defined by symptoms requiring antibiotic or systemic corticosteroid administration, on-treatment severe
COPD exacerbations, defined by deterioration requiring hospital admission, and pneumonia, defined by a
comprehensive list of pneumonia MedDRA-preferred terms applied to investigator-reported adverse
events [18]. A predefined on-treatment composite cardiovascular event outcome included cardiovascular
death, myocardial infarction, unstable angina, stroke, or transient ischaemic attack.
Analysis
Variable distribution was examined and summary statistics calculated within each BMI category. Using the
normal weight category as reference, the association between BMI category and time to event was
evaluated using Cox proportional hazards modelling, with competing risk methods applied for
cause-specific mortality outcomes. Analyses were adjusted for age, sex, region, race, ischaemic heart
disease indicator, vascular disease indicator, smoking status, cardiovascular entry criteria (history and risk
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by age), previous COPD exacerbations, per cent predicted FEV1, treatment arm and BMI (categorical) [13].
Interaction between treatment arm and BMI (categorical) was tested and was not significant.
Analyses were completed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Statistical
significance was defined as p<0.05.
Results
In total, 16485 participants were included in the analysis. A quarter (26.1%) of the sample were classified
as normal weight (n=4306), with 6.7% (n=1111) underweight, 34.3% overweight (n=5662), and 32.8%
obese (n=5406). Baseline characteristics stratified by BMI category are shown in table 1 and table 1S. Age,
lung function, and treatment assignment were similar across categories. Obese groups tended towards a
higher proportion of women, white participants, US origin, and prevalent (⩾2) COPD exacerbations in the
year prior to enrolment. Obese groups also demonstrated higher diabetes prevalence (including diabetes
with target organ disease), hypercholesterolaemia, and hypertension, though curiously lower prevalence of
previous stroke. Conversely, normal and underweight strata tended towards a higher proportion of Asian
race and origin, higher current smoking, and higher rates of peripheral arterial disease. Obese individuals
were more likely to report use of any of the long-acting inhaler therapies (β-agonist, muscarinic antagonist,
inhaled corticosteroids), and most reported cardiovascular therapies (table 2S).
Compared with the predefined normal weight strata (BMI 20–<25 kg·m−2), overweight and class I obese
individuals demonstrated 38% (95% CI 27–48%) and 25% (95% CI 10–38%) lower risk of death during
the duration of the trial, respectively (figure 1). Conversely, individuals who were underweight
demonstrated a 31% (95% CI 4–64%) increase in the risk of death (with similar rates when <20 kg·m−2
was split further into categories of underweight II (<18.5 kg·m−2) and underweight I (18.5–<20 kg·m−2),
table 4S), and individuals with class III obesity demonstrated a 36% (95% CI 0–86%) increase in the risk
of death compared with those with a normal BMI (figure 1). In all BMI strata, rates of death due to
cardiovascular disease were higher than those attributable to respiratory causes (table 2 and table 4S).
Respiratory deaths contributed more to mortality in the underweight (where 2.2% of patients died of
respiratory causes; HR 1.44, 95% CI 0.86–2.41) than the obese class III category (where 1.0% of patients
died; HR 1.31, 95% CI 0.54–3.16). Being overweight compared to having a lower BMI was associated
with a decreased hazard of both respiratory (HR 0.51, 95% CI 0.32–0.81) and cardiovascular (HR 0.69,
95% CI 0.53–0.88) mortality.
Regarding morbidity, being overweight was associated with a lower risk of severe COPD exacerbation (HR
0.85, 95% CI 0.73–0.98) or pneumonia (HR 0.76, 95% CI 0.63–0.91) during treatment, while class II
obesity was associated with a higher risk of moderate/severe COPD exacerbation (HR 1.14, 95% CI 1.01–
1.28). Underweight was conversely associated with a higher risk of pneumonia (HR 1.33, 95% CI 1.05–
1.67) compared to normal weight. No other significant, unique associations between BMI strata and
moderate/severe or severe COPD exacerbations or cardiovascular events were noted in the main analyses
(table 3) or sensitivity analyses (table 5S).
Discussion
Data from the large, international SUMMIT trial including patients with moderate COPD at heightened
cardiovascular risk demonstrates that BMI is associated with risk of all-cause mortality at the extremes;
specifically, among underweight (BMI <20 kg·m−2) and obese class III (BMI ⩾40 kg·m−2). Moderate
levels of obesity and overweight are associated with lower risk of death. Risk of death due to respiratory
causes is highest among underweight individuals, though the leading cause of death in all BMI categories
is cardiovascular, with the highest risk among obese class III. A “U-shaped” curve (with a protective
association with overweight) was not consistently identified for morbidity outcomes.
The findings support and extend several studies demonstrating that underweight is a substantial risk factor
for mortality in patients with COPD [1, 8, 19–21]. It has been argued that there is reverse causation with
increasing severity of illness coinciding with weight loss and underweight status [20]. While the ability of
nutritional supplementation and weight gain to reduce COPD mortality remains unclear [22, 23], the
relationship between underweight and mortality exists even within patients with mild or moderate disease
[8], suggesting that disease severity alone may not account for increased mortality among underweight.
Furthermore, findings in the SUMMIT population are consistent with prior studies demonstrating a
protective association between overweight and obesity and COPD mortality [2, 24–26]. The protective
associations with higher BMI are typically strongest with increasing disease severity [8], and are reflected
here in a population with moderate disease. In all categories, cardiovascular mortality predominated,
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Subjects n 1111 4306 5662 3452 1367 587
Demographics
BMI (kg·m−2) 18.3±1.3 22.9±1.4 27.4±1.4 32.1±1.4 37.0±1.4 44.0±4.0
Age years 65.4±8.4 65.8±8.0 65.5±7.9 65.0±7.5 63.4±7.8 62.3±7.8
Female 229 (21%) 941 (22%) 1373 (24%) 946 (27%) 455 (33%) 252 (43%)
Race
White 468 (42%) 2941 (68%) 4841 (85%) 3236 (94%) 1314 (96%) 557 (95%)
Asian 625 (56%) 1262 (29%) 694 (12%) 126 (4%) 13 (<1%) 3 (<1%)
Other 18 (2%) 103 (2%) 127 (2%) 90 (3%) 40 (3%) 27 (5%)
Region
USA 75 (7%) 443 (10%) 859 (15%) 655 (19%) 344 (25%) 214 (36%)
Europe 340 (31%) 2322 (54%) 3700 (65%) 2365 (69%) 889 (65%) 302 (51%)
Asia 625 (56%) 1245 (29%) 681 (12%) 120 (3%) 12 (<1%) 3 (<1%)
Rest of world 71 (6%) 296 (7%) 422 (7%) 312 (9%) 122 (9%) 68 (12%)
Current smokers 617 (56%) 2281 (53%) 2589 (46%) 1389 (40%) 570 (42%) 232 (40%)
Smoking history (pack-years) 39.1±23.6 40.4±23.4 40.2±23.8 41.8±25.1 42.4±27.1 41.9±26.3
Lung function
Post-BD FEV1 (L) at screening 1.5±0.4 1.6±0.4 1.7±0.4 1.7±0.4 1.7±0.4 1.7±0.4
% Predicted post-BD FEV1 at
screening
60.0±6.3 59.8±6.2 59.8±6.1 59.4±5.9 59.2±6.1 58.9±6.1
FEV1 reversibility (% of pre-BD FEV1)
at screening
7.6±12.2 8.1±12.2 8.1±11.6 8.0±12.0 9.0±12.4 9.0±12.2
Pre-study COPD exacerbations in 12 months before study
0 717 (65%) 2675 (62%) 3390 (60%) 2065 (60%) 828 (61%) 346 (59%)
1 233 (21%) 1009 (23%) 1418 (25%) 888 (26%) 338 (25%) 134 (23%)
⩾2 161 (14%) 622 (14%) 854 (15%) 499 (14%) 201 (15%) 107 (18%)
Cardiovascular inclusion criteria#
Manifest disease
Coronary artery disease 445 (40%) 2056 (48%) 2951 (52%) 1868 (54%) 745 (54%) 314 (53%)
Peripheral arterial disease 245 (22%) 841 (20%) 1096 (19%) 629 (18%) 234 (17%) 100 (17%)
Previous stroke 147 (13%) 439 (10%) 546 (10%) 309 (9%) 108 (8%) 46 (8%)
Previous myocardial infarction 144 (13%) 653 (15%) 967 (17%) 666 (19%) 246 (18%) 98 (17%)
Diabetes with target organ disease 58 (5%) 237 (6%) 458 (8%) 414 (12%) 230 (17%) 106 (18%)
At risk
Hypercholesterolaemia 547 (49%) 2467 (57%) 3579 (63%) 2300 (67%) 906 (66%) 391 (67%)
Hypertension 833 (75%) 3506 (81%) 4931 (87%) 3183 (92%) 1274 (93%) 538 (92%)
Diabetes mellitus 200 (18%) 818 (19%) 1395 (25%) 1103 (32%) 588 (43%) 272 (46%)
Peripheral arterial disease 130 (12%) 420 (10%) 564 (10%) 309 (9%) 100 (7%) 54 (9%)
SUMMIT treatment assignment
Fluticasone furoate 298 (27%) 1086 (25%) 1420 (25%) 860 (25%) 336 (25%) 135 (23%)
Vilanterol 280 (25%) 1061 (25%) 1400 (25%) 881 (26%) 325 (24%) 171 (29%)
Fluticasone furoate/vilanterol 280 (25%) 1052 (24%) 1437 (25%) 857 (25%) 344 (25%) 151 (26%)
Placebo 253 (23%) 1107 (26%) 1405 (25%) 854 (25%) 362 (26%) 130 (22%)
Data are presented as mean±SD or n (%), unless otherwise stated. FEV1: forced expiratory volume in 1 s; BD: bronchodilator.




















consistent with population studies demonstrating cardiovascular disease as a leading cause of death in
patients with COPD [11, 12, 27] and reasonable in this population at heightened cardiovascular risk.
Because of the large number of participants in the trial, there were a substantial number with class III
obesity. Although class I obesity was associated with a lower mortality risk, individuals with class III
obesity demonstrated increased risk for mortality. Indeed, weight gain in obese patients has previously
been associated with increased mortality in individuals with severe COPD [28]. While overall increased
mortality rates above 40 kg·m−2 might be expected based on well-known associations with hypertension,
hypercholesterolaemia, and diabetes, the prevalence of these conditions were similar between BMI classes
II and III at trial initiation, suggesting a potential alternative explanation. Other comorbidities not captured
in the SUMMIT data may play a role. For example, class III obesity is also associated with higher rates
of sleep apnoea [29], which is linked to increased mortality and is an important comorbidity in COPD
[30, 31]. Further, COPD phenotype may play a role in BMI–mortality relationships; patients with an
emphysematous phenotype are more likely to be underweight, whereas patients with a chronic bronchitis
phenotype are more likely to be overweight [32]. While these diagnoses are not mutually exclusive, it is




























































FIGURE 1 All-cause mortality by body mass index (BMI) category. Adjusted for age, sex, region, race, ischaemic
heart disease, vascular disease, smoking status, cardiovascular history/risk, previous COPD exacerbations,
% predicted forced expiratory volume in 1 s, treatment arm and BMI.













Subjects n 1111 4306 5662 3452 1367 587
Respiratory mortality
Deaths (%) 24 (2.2%) 49 (1.1%) 27 (0.5%) 23 (0.7%) 8 (0.6%) 6 (1.0%)
Hazard ratio (95% CI) 1.44 (0.86–2.41) Ref. 0.51 (0.32–0.81) 0.77 (0.46–1.30) 0.80 (0.37–1.72) 1.31 (0.54–3.16)
Cardiovascular mortality
Deaths (%) 41 (3.7%) 132 (3.1%) 119 (2.1%) 94 (2.7%) 35 (2.6%) 24 (4.1%)
Hazard ratio (95% CI) 1.30 (0.90–1.87) Ref. 0.69 (0.53–0.88) 0.90 (0.68–1.19) 1.04 (0.71–1.53) 1.87 (1.19–2.94)
Hazard ratio (95% CI) per Cox proportional hazards. Adjusted model accounts for age, sex, region, race, ischaemic heart disease indicator, vascular
disease indicator, smoking status, cardiovascular entry criteria (history and risk by age), previous COPD exacerbations, % predicted forced
expiratory volume in 1 s, treatment arm and BMI.
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Few studies in the current literature have examined associations between BMI and COPD morbidity
outcomes, although several have combined morbidity and mortality into a single variable [24, 33]. These
studies overall demonstrate increased respiratory morbidity in the underweight (i.e. hospitalisations [33],
hospital length of stay [24], pneumonia [18]), although at least one previous analysis suggests higher odds
of severe COPD exacerbation at the opposite end of the BMI spectrum, class III obesity [34]. Extreme
obesity may confer disadvantageous changes in pulmonary function such as increased airway resistance
and reduced lung volumes [35], relevant to individuals with COPD with already compromised respiratory
mechanics. It is plausible that this may contribute to respiratory morbidity and exacerbations. Interestingly,
in the SUMMIT trial population, overweight was associated with a lower risk of pneumonia. This is
consistent with previous findings in the TORCH trial [36] demonstrating lower rates of pneumonia in
higher BMI groups [18]. Furthermore, overweight was associated with a lower risk of severe COPD
exacerbations, but no increased risk was noted in underweight or class III obese populations. In contrast to
overweight, lower mortality rates in class I obesity were not matched with reduced morbidity for the
measured outcomes, suggesting the potential for an unmeasured morbidity signal. We did not find an
association between BMI category and cardiovascular event risk; previous studies of cardiovascular
morbidity outcomes in COPD by BMI are sparse, but suggest higher prevalence of heart failure with
obesity, though not necessarily stroke or coronary heart disease [34, 37, 38], which comprise the majority
of the events captured in the SUMMIT trial. The discordance between morbidity and mortality outcomes
in relation to BMI deserves further attention, and the selection of outcomes is important in defining any
future nutritional intervention trials.
Strengths include a study design that allowed for longitudinal assessment of a large number of participants
including a critical population with obesity class III, limited in previous COPD studies. Patients with
severe and very severe COPD were excluded, providing the opportunity to investigate the paradox in a
dedicated cohort with less-severe COPD, which may mitigate confounding of lower weight by higher
disease severity. Cardiovascular risk was defined, allowing for adjustment but also mitigating competing
respiratory risk in cause-specific mortality analyses. Deaths within the study were carefully adjudicated,
with high ascertainment of vital status and confidence in primary and secondary outcomes. Ability to
define cause-specific morbidity and mortality outcomes in a single population is unique. International
representation increases generalisability of results, while precise characterisation of lung function and
rigorous assessment of cardiovascular health enhances validity of application among populations with
moderate COPD at heightened cardiovascular risk.
Weaknesses are acknowledged. While cardiovascular comorbidities were well defined, additional
comorbidities were not captured, limiting assessment of potential contributing factors. Furthermore, the
relatively small number of cardiovascular events (compared with all-cause mortality) may have limited




















Events (%) 325 (29.3%) 1206 (28.0%) 1551 (27.4%) 1005 (29.1%) 429 (31.4%) 188 (32.0%)
Hazard ratio (95% CI) 1.01 (0.89–1.14) Ref. 0.97 (0.90–1.05) 1.02 (0.93–1.11) 1.14 (1.01–1.28) 1.05 (0.89–1.23)
Severe COPD exacerbation¶
Events (%) 128 (11.5%) 367 (8.5%) 384 (6.8%) 265 (7.7%) 105 (7.7%) 44 (7.5%)
Hazard ratio (95% CI) 1.18 (0.96–1.46) Ref. 0.85 (0.73–0.98) 1.02 (0.87–1.21) 1.14 (0.90–1.43) 1.07 (0.77–1.49)
Pneumonia
Events (%) 106 (9.5%) 260 (6.0%) 235 (4.2%) 153 (4.4%) 58 (4.2%) 26 (4.4%)
Hazard ratio (95% CI) 1.33(1.05–1.67) REF. 0.76 (0.63–0.91) 0.83(0.67–1.03) 0.84(0.62–1.14) 0.80(0.52–1.22)
Composite cardiovascular events+
Events (%) 46 (4.1%) 191 (4.4%) 231 (4.1%) 154 (4.5%) 47 (3.4%) 19 (3.2%)
Hazard ratio (95% CI) 1.01 (0.73–1.40) Ref. 0.90 (0.74–1.10) 0.98 (0.78–1.22) 0.88 (0.64–1.23) 0.93 (0.57–1.50)
Hazard ratio (95% CI) per Cox proportional hazards. Adjusted model accounts for age, sex, region, race, ischaemic heart disease indicator, vascular
disease indicator, smoking status, cardiovascular entry criteria (history and risk by age), previous COPD exacerbations, % predicted forced
expiratory volume in 1 s, treatment arm and BMI. #: moderate COPD exacerbations were exacerbation treated with antibiotics and/or systemic
corticosteroids; ¶: severe COPD exacerbations were those that required hospitalisation; +: composite cardiovascular events were predefined
secondary end-points, contains myocardial infarction, stroke, transient ischaemic attack, unstable angina, and on-treatment cardiovascular death.
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power to distinguish between BMI groupings. In this study, a BMI of 20 kg·m−2 was chosen as the lower
limit of the normal weight category for primary analyses. This cut-off point may reduce comparability with
other disease states, and falls between the BMI of 21 kg·m−2 in the BODE index [39] and 18.5 kg·m−2 in
WHO guidelines [17] to define at-risk/underweight populations. However, 20 kg·m−2 has been used in
previous studies demonstrating the obesity paradox in populations with COPD [24, 25], and is of proposed
benefit in facilitating international comparisons [40]. This approach combined with sensitivity analyses
using the cut-off point of BMI 18.5 kg·m−2, provides increased granularity and generalisability. History of
smoking was an inclusion criterion in the trial, and so differential associations among smokers/nonsmokers
and resultant selection bias by smoking was not explored [41]. Residual confounding by region may exist.
Underweight individuals were more likely to be enrolled in Asia, whereas obese class II/III individuals
were more likely enrolled in Europe and the USA, and outcomes may be influenced by local patterns of
medical care and exposures. Adjustment for additional covariates not available within the SUMMIT data
may provide more precision in estimates, and reveal factors that adjust or modify the obesity–mortality
association in the direction of protection or harm. Multi-collinearity was not assessed. While
multi-collinearity has the potential to decrease precision and skew estimates, presented crude death rates
mirror the adjusted pattern, and variable inclusion was determined on the basis of clinical relevance and
aim to isolate direct BMI associations, avoiding mediation and confounding where possible. Further,
collider stratification bias should be considered as a partial or complete methodologic explanation for
findings of a protective association with obesity, and bears mention and consideration as an alternative to
causality [42, 43]. COPD sub-phenotyping, including imaging or symptom data, was not available for
further stratification or adjustment. Finally, all patients were selected for inclusion in a randomised
controlled trial and may therefore differ from patients in the general population; caution is warranted in
application to populations outside of the trial inclusion criteria.
In conclusion, we have demonstrated a U-shaped curve in the association between BMI category and
mortality in an international population with moderate COPD at heightened cardiovascular risk. This
relationship extends previous studies demonstrating increased risk of mortality in underweight, and a
protective association between overweight and moderate obesity. However, we provide evidence supporting
recurrence of increased mortality risk with extreme obesity, at BMI ⩾40 kg·m−2. Understanding the impact
of overweight and obesity on COPD is paramount in the context of rising numbers of individuals with
COPD [44] and shifts in prevalence of overweight and obesity worldwide [45]. The relationship described
emphasises the need to better understand the impact of BMI-driven nutritional supplementation and weight
loss interventions when applied to populations with COPD.
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